<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02239211</url>
  </required_header>
  <id_info>
    <org_study_id>RG_13-027</org_study_id>
    <secondary_id>2014-002393-37</secondary_id>
    <nct_id>NCT02239211</nct_id>
  </id_info>
  <brief_title>A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis</brief_title>
  <acronym>BUTEO</acronym>
  <official_title>A Single Arm, Two-stage, Multi-centre, Phase II Clinical Trial Investigating the Safety and Activity of the Use of BTT1023 Targeting Vascular Adhesion Protein (VAP-1), in the Treatment of Patients With Primary Sclerosing Cholangitis (PSC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotie Therapies Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study to determine the safety and preliminary efficacy of a human&#xD;
      monoclonal antibody (BTT1023) which targets the vascular adhesion protein (VAP-1) and its use&#xD;
      in the treatment of patients with primary sclerosing cholangitis (PSC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary sclerosing cholangitis is a progressive immune mediated biliary disease characterised&#xD;
      by bile duct inflammation and fibrosis, and accompanying hepatic fibrosis. For patients with&#xD;
      elevated alkaline phosphatase (ALP) in particular, progressive disease is predicted, that&#xD;
      currently results in a need for liver transplantation in the majority. No current medical&#xD;
      therapy has as yet been shown to be effective in altering the natural history of disease. For&#xD;
      this reason patients with PSC with elevated ALP values will be recruited to this study, to&#xD;
      evaluate the impact of Vap-1 blockade by BTT1023, in an early phase study focused on&#xD;
      biochemical efficacy and safety.&#xD;
&#xD;
      This is an early phase study of BTT1023 in immune mediated liver disease, with the rationale&#xD;
      to identify biochemical efficacy of effect (reduction in ALP) and safety, in an orphan&#xD;
      disease indication for PSC that presently lacks any other medical therapy. The study design&#xD;
      therefore focuses on identifying early biochemical efficacy signals to justify larger scale,&#xD;
      randomised controlled studies over longer duration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 8, 2015</start_date>
  <completion_date type="Actual">October 23, 2018</completion_date>
  <primary_completion_date type="Actual">October 23, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response at Visit 10 (Day 99): a reduction in serum ALP by 25% or more from baseline to Visit 10 (Day 99)</measure>
    <time_frame>99 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Compliance (including patient withdrawal)</measure>
    <time_frame>120 days</time_frame>
    <description>These will be measured to evaluate the tolerability of BTT1203 in patients with PSC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Event (SAE) frequency</measure>
    <time_frame>120 days</time_frame>
    <description>These will be measured to evaluate the safety, effective dose, and tolerability of BTT1203 in patients with PSC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event (AE) frequency</measure>
    <time_frame>120 days</time_frame>
    <description>These will be measured to evaluate the safety, effective dose, and tolerability of BTT1203 in patients with PSC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of any change (improvement or worsening) from baseline to Day 99 in the quality of life questionnaire EQ-5D</measure>
    <time_frame>99 days</time_frame>
    <description>Using validated EQ-5D scoring system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of any change (improvement or worsening) from baseline to Day 99 in the quality of life questionnaire Fatigue Severity Scale</measure>
    <time_frame>99 days</time_frame>
    <description>The scoring is done by calculating the average response to the questions (adding up all the answers and dividing by nine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of any change (improvement or worsening) from baseline to Day 99 in the quality of life questionnaire Pruritus Visual Analogue Score</measure>
    <time_frame>99 days</time_frame>
    <description>VAS measured as per guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of any change (improvement or worsening) from baseline to Day 99 in Inflammatory Bowel Disease Diaries (if applicable)</measure>
    <time_frame>99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of any change (improvement or worsening) from baseline to Day 99 in enhanced liver fibrosis test</measure>
    <time_frame>99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of any change (improvement or worsening) from baseline to Day 99 in Fibroscan measures</measure>
    <time_frame>99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of any change (improvement or worsening) from baseline to Day 99 in Aspartate Transaminase (AST)</measure>
    <time_frame>99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of any change (improvement or worsening) from baseline to Day 99 in Alanine Transaminase (ALT)</measure>
    <time_frame>99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of any change (improvement or worsening) from baseline to Day 99 in Alkaline Phosphatase (ALP)</measure>
    <time_frame>99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of any change (improvement or worsening) from baseline to Day 99 in Gamma Glutamyl Transferase (GGT)</measure>
    <time_frame>99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of any change (improvement or worsening) from baseline to Day 99 in Bilirubin</measure>
    <time_frame>99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of any change (improvement or worsening) from baseline to Day 99 in Albumin</measure>
    <time_frame>99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of any change (improvement or worsening) from baseline to Day 99 in International Normalised Ratio (INR)</measure>
    <time_frame>99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of any change (improvement or worsening) from baseline to Day 99 in Mayo PSC Risk Score</measure>
    <time_frame>99 days</time_frame>
    <description>PSC Risk score calculated as per The Revised Natural History Model for Primary Sclerosing Cholangitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of any change (improvement or worsening) from baseline to Day 99 in Model for End Stage Liver Disease (MELD) Score</measure>
    <time_frame>99 days</time_frame>
    <description>MELD calculated as per pre 2016 guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate changes (improvement or worsening) in sVAP-1/SSAO as a biomarker of liver disease activity across the trial period</measure>
    <time_frame>120 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <arm_group>
    <arm_group_label>BTT1023</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BTT1023 8mg/kg IV infusion, total of 7 infusions over 11 weeks. Duration 1-2 hours per infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BTT1023</intervention_name>
    <description>IV (in the vein) Investigational Medicinal Product (IMP)</description>
    <arm_group_label>BTT1023</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females 18 - 75 years of age who are willing and able to provide informed,&#xD;
             written consent and comply with all trial requirements&#xD;
&#xD;
          2. Clinical diagnosis of PSC as evident by chronic cholestasis of more than six months&#xD;
             duration with either a consistent MRI showing sclerosing cholangitis or a liver biopsy&#xD;
             consistent with PSC in the absence of a documented alternative aetiology for&#xD;
             sclerosing cholangitis&#xD;
&#xD;
          3. In those with concomitant Inflammatory Bowel Disease, clinical and colonoscopic&#xD;
             evidence, (in line with the patient's standard of care; within 18 months) of stable&#xD;
             disease, without findings of high grade dysplasia&#xD;
&#xD;
          4. In those on treatment with UDCA, therapy must be stable for at least 3 months, and at&#xD;
             a dose not greater than 20 mg/kg/day. In those not on treatment with UDCA at the time&#xD;
             of screening, a minimum of 8 weeks since the last dose of UDCA should be recorded&#xD;
&#xD;
          5. Serum ALP greater than 1.5 x ULN&#xD;
&#xD;
          6. Stable serum ALP levels (levels must not change by more than 25% from Screening Visit&#xD;
             1 and Screening Visit 2)&#xD;
&#xD;
          7. Female subjects of childbearing potential must have a negative pregnancy test prior to&#xD;
             starting trial treatment. For the purposes of this trial, a female subject of&#xD;
             childbearing potential is a woman who has not had a hysterectomy, bilateral&#xD;
             oophorectomy, or medically-documented ovarian failure. Women ≤ 50 years of age with&#xD;
             amenorrhea of any duration will be considered to be of childbearing potential&#xD;
&#xD;
          8. All sexually active women of childbearing potential must agree to use two forms of&#xD;
             highly effective method of contraception from the Screening Visit throughout the trial&#xD;
             period and for 99 days following the last dose of trial drug. If using hormonal agents&#xD;
             the same method must have been used for at least 1 month before trial dosing and&#xD;
             subjects must use a barrier method as the other form of contraception. Lactating women&#xD;
             must agree to discontinue breast feeding before trial investigational medicinal&#xD;
             product administration&#xD;
&#xD;
          9. Men, if not vasectomised, must agree to use barrier contraception (condom plus&#xD;
             spermicide) during heterosexual intercourse from screening through to trial completion&#xD;
             and for 99 days from the last dose of trial investigational medicinal product&#xD;
&#xD;
         10. Patients must weigh ≥ 40 kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of documented secondary sclerosing cholangitis on prior clinical&#xD;
             investigations&#xD;
&#xD;
          2. Presence of alternative causes of liver disease, that are considered by the&#xD;
             Investigator to be the predominant active liver injury at the time of screening,&#xD;
             including viral hepatitis, alcoholic liver disease, non-alcoholic steatohepatitis,&#xD;
             primary biliary cirrhosis. Patients with possible overlap syndrome with autoimmune&#xD;
             hepatitis are excluded if the Investigator considers autoimmune hepatitis as the&#xD;
             predominant liver injury&#xD;
&#xD;
          3. AST and ALT &gt;10 x ULN or bilirubin &gt;3 x ULN or INR &gt;1.3 in the absence of&#xD;
             anti-coagulants&#xD;
&#xD;
          4. Serum creatinine &gt;130μmol/L or platelet count &lt;50 x 109/L&#xD;
&#xD;
          5. Any evidence of hepatic decompensation past or present, including ascites, episodes of&#xD;
             hepatic encephalopathy or variceal bleeding&#xD;
&#xD;
          6. Recent cholangitis within last 90 days or ongoing need for prophylactic antibiotics&#xD;
&#xD;
          7. Pregnancy or breast feeding&#xD;
&#xD;
          8. Harmful alcohol consumption as evaluated by the Investigator&#xD;
&#xD;
          9. Flare in colitis activity within last 90 days requiring intensification of therapy&#xD;
             beyond baseline maintenance treatment; use of oral prednisolone &gt;10 mg/day, biologics&#xD;
             (i.e. monoclonal antibodies) and or hospitalisation for colitis within 90 days. Prior&#xD;
             use of biologics is not a contraindication to screening&#xD;
&#xD;
         10. Diagnosed cholangiocarcinoma or high clinical suspicion of cholangiocarcinoma either&#xD;
             clinically or by imaging&#xD;
&#xD;
         11. Concurrent malignancies or invasive cancers diagnosed within past 3 years except for&#xD;
             adequately treated basal cell and squamous cell carcinoma of the skin and in situ&#xD;
             carcinoma of the uterine cervix&#xD;
&#xD;
         12. Presence of a percutaneous drain or bile duct stent&#xD;
&#xD;
         13. Major surgical procedure within 30 days of screening&#xD;
&#xD;
         14. Prior organ transplantation&#xD;
&#xD;
         15. Known hypersensitivity to the investigational product or any of its formulation&#xD;
             excipients&#xD;
&#xD;
         16. Unavailable for follow-up assessment or concern for subject's compliance&#xD;
&#xD;
         17. Participation in an investigational trial of a drug or device within 60 days of&#xD;
             screening or 5 half lives of the last dose of investigational drug, where the trial&#xD;
             drug half-life is greater than 12 days&#xD;
&#xD;
         18. Any other condition that in the opinion of the Investigator renders the subject a poor&#xD;
             risk for inclusion into the trial&#xD;
&#xD;
         19. Positive screening test for tuberculosis (TB) (including T-SPOT.TB TB test), unless&#xD;
             respiratory review confirms false positive test results&#xD;
&#xD;
         20. Receipt of live vaccination within 6 weeks prior to Screening Visit 2&#xD;
&#xD;
         21. Known HIV positive status&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Newsome, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queens Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 4, 2014</study_first_submitted>
  <study_first_submitted_qc>September 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2014</study_first_posted>
  <last_update_submitted>April 30, 2019</last_update_submitted>
  <last_update_submitted_qc>April 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BUTEO</keyword>
  <keyword>Primary sclerosing cholangitis</keyword>
  <keyword>PSC</keyword>
  <keyword>VAP-1</keyword>
  <keyword>BTT1023</keyword>
  <keyword>Human monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02239211
org study id: RG_13-027
secondary id: 2014-002393-37
nct id: NCT02239211
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
has dmc: Yes
This is a phase II study to determine the safety and preliminary efficacy of a human
      monoclonal antibody (BTT1023) which targets the vascular adhesion protein (VAP-1) and its use
      in the treatment of patients with primary sclerosing cholangitis (PSC).
Primary sclerosing cholangitis is a progressive immune mediated biliary disease characterised
      by bile duct inflammation and fibrosis, and accompanying hepatic fibrosis. For patients with
      elevated alkaline phosphatase (ALP) in particular, progressive disease is predicted, that
      currently results in a need for liver transplantation in the majority. No current medical
      therapy has as yet been shown to be effective in altering the natural history of disease. For
      this reason patients with PSC with elevated ALP values will be recruited to this study, to
      evaluate the impact of Vap-1 blockade by BTT1023, in an early phase study focused on
      biochemical efficacy and safety.

      This is an early phase study of BTT1023 in immune mediated liver disease, with the rationale
      to identify biochemical efficacy of effect (reduction in ALP) and safety, in an orphan
      disease indication for PSC that presently lacks any other medical therapy. The study design
      therefore focuses on identifying early biochemical efficacy signals to justify larger scale,
      randomised controlled studies over longer duration.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Response at Visit 10 (Day 99): a reduction in serum ALP by 25% or more from baseline to Visit 10 (Day 99)
time frame: 99 days
measure: Treatment Compliance (including patient withdrawal)
time frame: 120 days
description: These will be measured to evaluate the tolerability of BTT1203 in patients with PSC
measure: Serious Adverse Event (SAE) frequency
time frame: 120 days
description: These will be measured to evaluate the safety, effective dose, and tolerability of BTT1203 in patients with PSC
measure: Adverse Event (AE) frequency
time frame: 120 days
description: These will be measured to evaluate the safety, effective dose, and tolerability of BTT1203 in patients with PSC
measure: Calculation of any change (improvement or worsening) from baseline to Day 99 in the quality of life questionnaire EQ-5D
time frame: 99 days
description: Using validated EQ-5D scoring system
measure: Calculation of any change (improvement or worsening) from baseline to Day 99 in the quality of life questionnaire Fatigue Severity Scale
time frame: 99 days
description: The scoring is done by calculating the average response to the questions (adding up all the answers and dividing by nine).
measure: Calculation of any change (improvement or worsening) from baseline to Day 99 in the quality of life questionnaire Pruritus Visual Analogue Score
time frame: 99 days
description: VAS measured as per guidelines
measure: Calculation of any change (improvement or worsening) from baseline to Day 99 in Inflammatory Bowel Disease Diaries (if applicable)
time frame: 99 days
measure: Calculation of any change (improvement or worsening) from baseline to Day 99 in enhanced liver fibrosis test
time frame: 99 days
measure: Calculation of any change (improvement or worsening) from baseline to Day 99 in Fibroscan measures
time frame: 99 days
measure: Calculation of any change (improvement or worsening) from baseline to Day 99 in Aspartate Transaminase (AST)
time frame: 99 days
measure: Calculation of any change (improvement or worsening) from baseline to Day 99 in Alanine Transaminase (ALT)
time frame: 99 days
measure: Calculation of any change (improvement or worsening) from baseline to Day 99 in Alkaline Phosphatase (ALP)
time frame: 99 days
measure: Calculation of any change (improvement or worsening) from baseline to Day 99 in Gamma Glutamyl Transferase (GGT)
time frame: 99 days
measure: Calculation of any change (improvement or worsening) from baseline to Day 99 in Bilirubin
time frame: 99 days
measure: Calculation of any change (improvement or worsening) from baseline to Day 99 in Albumin
time frame: 99 days
measure: Calculation of any change (improvement or worsening) from baseline to Day 99 in International Normalised Ratio (INR)
time frame: 99 days
measure: Calculation of any change (improvement or worsening) from baseline to Day 99 in Mayo PSC Risk Score
time frame: 99 days
description: PSC Risk score calculated as per The Revised Natural History Model for Primary Sclerosing Cholangitis
measure: Calculation of any change (improvement or worsening) from baseline to Day 99 in Model for End Stage Liver Disease (MELD) Score
time frame: 99 days
description: MELD calculated as per pre 2016 guidelines
measure: Evaluate changes (improvement or worsening) in sVAP-1/SSAO as a biomarker of liver disease activity across the trial period
time frame: 120 days
arm group label: BTT1023
arm group type: Experimental
description: BTT1023 8mg/kg IV infusion, total of 7 infusions over 11 weeks. Duration 1-2 hours per infusion.
intervention type: Drug
intervention name: BTT1023
description: IV (in the vein) Investigational Medicinal Product (IMP)
arm group label: BTT1023
criteria: 
gender: All
minimum age: 18 Years
maximum age: 75 Years
healthy volunteers: No
last name: Philip Newsome, MD
role: Principal Investigator
affiliation: University of Birmingham
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: United Kingdom
responsible party type: Sponsor
mesh term: Cholangitis
mesh term: Cholangitis, Sclerosing
sharing ipd: No